Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. D'Annunzio", Chieti, Pescara, Italy.
Department of Pharmacy, University "G. D'Annunzio", Chieti, Pescara, Italy.
Immun Inflamm Dis. 2023 Feb;11(2):e771. doi: 10.1002/iid3.771.
It is important to block SARS-CoV-2 infection immediately with early therapies, such as monoclonal antibodies (MonoAbs). Also, several studies show that obesity is associated with a high risk of severe COVID-19 disease. We enrolled 32 SARS-CoV-2 infected patients who received MonoAbs, all patients were not vaccinated for SARS-CoV-2, and they received therapy after 7 ± 2 days from the onset of COVID-19 symptoms. In the days following administration, patients followed home therapy with Pidotimod 800 mg bid for 10 days and cholecalciferol 2000 UI for 20 days, prescribed the same day they received MonoAbs therapy. Our study found that there are no differences in the therapeutic response between obese and nonobese patients with SARS-CoV-2 infection undergoing MonoAbs therapy, in fact, none of them underwent hospitalization. Furthermore, the effect of the immunostimulant Pidotimod and cholecalciferol may have contributed to the resolution of COVID-19 symptoms in these patients.
立即使用早期疗法（例如单克隆抗体[MonoAbs]）阻断 SARS-CoV-2 感染非常重要。此外，多项研究表明肥胖与 COVID-19 重症的高风险相关。我们招募了 32 名感染了 SARS-CoV-2 的接受 MonoAbs 治疗的患者，所有患者均未接种 SARS-CoV-2 疫苗，他们在 COVID-19 症状出现后 7 ± 2 天接受了治疗。在给药后的几天里，患者在家中接受 pidotimod 800mg bid 和胆钙化醇 2000UI 治疗，共 10 天和 20 天，与接受 MonoAbs 治疗的同一天开出处方。我们的研究发现，肥胖和非肥胖的 SARS-CoV-2 感染患者在接受 MonoAbs 治疗时，其治疗反应没有差异，实际上他们都没有住院。此外，免疫刺激剂 pidotimod 和胆钙化醇的作用可能有助于这些患者 COVID-19 症状的缓解。
